FCH
GSK icon

Freestone Capital Holdings’s GSK GSK Stock Holding History

Freestone Capital Holdings’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,802
Closed -$210K – 663
2026
Q1 		$210K Buy
+3,802
New +$206K 0.01% 512
2024
Q4 		– Sell
-7,027
Closed -$287K – 460
2024
Q3 		$287K Sell
7,027
-181
-3% -$7.41K 0.01% 364
2024
Q2 		$278K Sell
7,208
-1,575
-18% -$66.3K 0.01% 396
2024
Q1 		$377K Sell
8,783
-605
-6% -$24.9K 0.01% 341
2023
Q4 		$348K Sell
9,388
-1,435
-13% -$51.5K 0.02% 305
2023
Q3 		$392K Sell
10,823
-1,674
-13% -$59.4K 0.02% 269
2023
Q2 		$445K Sell
12,497
-3,056
-20% -$110K 0.02% 267
2023
Q1 		$553K Buy
15,553
+2,659
+21% +$93K 0.02% 242
2022
Q4 		$453K Sell
12,894
-20,888
-62% -$696K 0.02% 257
2022
Q3 		$994K Buy
+33,782
New +$1.28M 0.04% 196
2022
Q2 		– Sell
-74,170
Closed -$4.04M – 493
2022
Q1 		$4.04M Buy
74,170
+5,260
+8% +$286K 0.16% 129
2021
Q4 		$3.8M Sell
68,910
-1,872
-3% -$97.4K 0.16% 131
2021
Q3 		$3.38M Buy
70,782
+402
+0.6% +$20.2K 0.17% 137
2021
Q2 		$3.5M Sell
70,380
-250
-0.4% -$12K 0.18% 138
2021
Q1 		$3.15M Sell
70,630
-3,051
-4% -$138K 0.17% 139
2020
Q4 		$3.39M Buy
73,681
+19,765
+37% +$908K 0.2% 124
2020
Q3 		$2.54M Sell
53,916
-6,332
-11% -$317K 0.17% 131
2020
Q2 		$3.07K Buy
60,248
+2,032
+3% +$104K 0.04% 119
2020
Q1 		$2.76K Sell
58,216
-48,155
-45% -$2.57M 0.06% 112
2019
Q4 		$6.25K Sell
106,371
-35,195
-25% -$1.96M 0.13% 56
2019
Q3 		$7.55K Sell
141,566
-43,114
-23% -$2.22M 0.18% 40
2019
Q2 		$9.24K Sell
184,680
-23,268
-11% -$1.17M 0.24% 35
2019
Q1 		$10.9M Sell
207,948
-14,885
-7% -$744K 0.64% 41
2018
Q4 		$10.6M Buy
222,833
+4,991
+2% +$246K 0.72% 36
2018
Q3 		$10.9M Sell
217,842
-6,601
-3% -$335K 0.07% 45
2018
Q2 		$11.3M Buy
224,443
+9,562
+4% +$482K 0.07% 47
2018
Q1 		$10.5M Buy
214,881
+144,099
+204% +$6.71M 0.61% 45
2017
Q4 		$3.14M Sell
70,782
-11,031
-13% -$510K 0.22% 120
2017
Q3 		$4.15M Buy
81,813
+6,607
+9% +$335K 0.3% 104
2017
Q2 		$4.05M Buy
75,206
+8,013
+12% +$427K 0.32% 81
2017
Q1 		$3.54M Buy
67,193
+11,448
+21% +$581K 0.27% 86
2016
Q4 		$2.68M Buy
+55,745
New +$2.75M 0.23% 110
2016
Q2 		– Sell
-38,985
Closed -$1.98M – 325
2016
Q1 		$1.98M Buy
38,985
+3,675
+10% +$183K 0.21% 87
2015
Q4 		$1.78M Sell
35,310
-11,777
-25% -$600K 0.18% 81
2015
Q3 		$2.26M Buy
47,087
+32,537
+224% +$1.69M 0.25% 61
2015
Q2 		$757K Buy
+14,550
New +$819K 0.12% 135
2014
Q1 		– Sell
-6,725
Closed -$449K – 258
2013
Q4 		$449K Sell
6,725
-545
-7% -$35.3K 0.08% 205
2013
Q3 		$456K Buy
7,270
+72
+1% +$4.63K 0.08% 234
2013
Q2 		$450K Buy
+7,198
New +$457K 0.09% 204

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Freestone Capital Holdings's GSK Position: Q2 2026 in Review

Freestone Capital Holdings sold out of GSK (GSK) in Q2 2026, closing a stake of 3,802 shares — an estimated $210K sold.

Freestone Capital Holdings first reported a position in GSK in Q2 2013 and held it in 39 quarters. The position peaked at $11.3M in Q2 2018. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Freestone Capital Holdings reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Freestone Capital Holdings sold 3,802 GSK shares in Q2 2026, an estimated $210K.
  • Freestone Capital Holdings first reported a position in GSK in Q2 2013 and held it in 39 quarters.
  • Freestone Capital Holdings's GSK position peaked at $11.3M in Q2 2018.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.